Winchester MD Leads Sponsorship of IC3 London

LONDON, 12th July 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that it was lead sponsor and an exhibitor at the Inaugural Institutional Capital & Cannabis Conference (Europe) in London.

IC3 forums are a meeting place for investors who wish to learn more about cannabis companies and investment funds who are looking to raise money or showcase their products, and professional service providers who facilitate these groups doing business.

IC3 conferences have earned a reputation in the US for quality content, expert speakers, and a high representation of institutional investors among its delegates. Winchester’s co-founder, Dan Kriznic, and its legal counsel, Fraser McGee both sat on industry expert panels and CEO, Faz Moshfeghi, was interviewed on stage in a strategic session led by Tristan Gervais, the London leader of Canaccord Genuity’s Cannabis sector team.

Faz Moshfeghi, CEO of Winchester MD commented: “We are delighted both with the new contacts we made at IC3 and with the positive feedback from investors and industry stakeholders on our exciting expansion strategy to build on our profitable UK on-line cannabis superstore”.

For more information, please visit www.winchestermd.com

On Behalf of the Board,

Faz Moshfeghi
CEO
Info@winchestermd.com

 About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

Winchester MD Acquires Stake In Harvard Based Synthetic Cannabis Company

LONDON, June 13th, 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that it has acquired a minority position in Boston, Massachusetts based private synthetic cannabis company Biotii Technologies Corp.(“Biotii”), created and managed by a group of highly qualified MIT and Harvard health care professionals.

Biotii is actively pursuing genetically engineered microorganisms that express cannabinoid profiles identical to those found in nature – at a fraction of the cost of current cannabis production methods. The scalable synthesizing process will enable the manufacture of lesser-known cannabis compounds, as well as well as tetrahydrocannabinol (THC) and cannabidiol (CBD), at materially lower costs when compared to conventional cultivation and extraction processes.

Traditional cultivation of cannabis plants for the purpose of extracting cannabidiolic acid (CBDA),  including medical THC and CBD is a time, labor and resource intensive endeavor that can result in depressed extraction yields of approximately 2.5%. An alternative tool to produce cannabinoids is biosynthetic engineering, where single cell organisms are programmed to synthesize the enzymes for the metabolic pathway that generates cannabinoids from sugars. Biotii intends to leverage a unique system to mass manufacture large quantities of cannabinoids with a smaller environmental footprint than other known methods.

By 2020, the Biotii team intends to establish processes to mass-produce CBD and medical THC in large quantities (in excess of one hundred metric tons per annum) and boast stable, consistent yields with pharmaceutical grade purities, with the lowest production costs in the industry.

Biotii has in recent times significantly advanced its business plans to include the announced investment on 4th April 2019 from ICC International Cannabis Corp. ((CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (“ICC”) and the subsequent entry into a design and automation agreement (the “Agreement”) with Y Combinator backed Opentrons Labworks Inc. alongside ICC. The Companies will collaborate to architect and construct Canada’s first privately owned high-throughput Bioworks Foundry. The Bioworks Foundry will function as a staging ground for Biotii’s cannabinoid researchers and organism designers to manufacture and analyze prototype enzyme pathways. The state-of-the-art facility will afford International Cannabis and Biotii the ability to scale its synthesized cannabinoid testing processes in a rapid and cost effective fashion. The announcement details can be found in full at: https://intlcannabiscorp.com/news/icc-biotii-y-combinator-backed-biotech-innovator-to-build-bioworks-foundry/

Dr Harrold, CEO, is an MIT instructor with expertise in end-to-end bio-lab management. He is also an entrepreneur having started four start-ups, including two funded by the National Science Foundation. Similarly, Biotii’s chief product officer Sisi Ni is an MIT trained materials scientist and engineer who was previously named as one of Forbes’ 30 under 30’s. Biotii has formed key relationships with leading medical research institutions in both the US and China.

“Biotii has a team of professionals from Harvard and MIT who are looking to disrupt the cannabis space by creating cannabinoids from glucose. This technology would significantly reduce the cost of input for our products which ultimately will bring increased shareholder value” said Faz Moshfeghi, CEO and Co-Founder of Winchester.

For more information, please visit www.winchestermd.com

On Behalf of the Board,
Faz Moshfeghi
CEO
Info@winchestermd.com

About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

 Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

Announcement Of Chief Financial Officer Appointment

LONDON, 03rd June 2019 –WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that on 28thMay 2019 the Company appointed Ewan Phillips as the Chief Financial Officer of the Company.

Ewan started his career at Deloitte focusing initially on audit and subsequently corporate finance. After Deloitte he spent 17 years on the Board of Deltex Medical Group plc (LON:DEMG) – an innovative UK Life Sciences company, where, as CFO, he led the company to an IPO on AIM gaining valuable exposure to raising capital, investor relations, corporate governance and scaling the business from 15 to over 100 employees and 20x sales growth. Ewan has completed over 50 financing transactions raising over £250 million and over 50 M&A transactions with an aggregate value in excess of £1 billion. He is a Chartered Accountant.

Faz Moshfeghi, CEO and Co-founder of the Company added: “As the business of the Company continues to grow and gather momentum the management made the recent decision to find and bring on board a relevant and successful accounting professional as our CFO. In Ewan we have secured a very experienced and important member of the team to assist with our aggressive acquisition and markets strategy. He will be a valuable member of the team that adds to and complements the talents of the existing management structure that will further enable us.”

For more information, please visitwww.winchestermd.com

On Behalf of the Board,
Faz Moshfeghi
CEO
Info@winchestermd.com

 About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

Winchester MD Appoints Chief Legal Officer And Regulatory Affairs

LONDON, UK, 13 May 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that on 09 May 2019 the Company appointed Fraser McGee (“McGee”) as Chief Legal Officer and Regulatory Affairs at its head office in London.

McGee is a UK qualified solicitor who has specialised in corporate finance and investment fund work with prominent law firms in the UK before moving to work in in-house with investment banks. He was also admitted as a solicitor of the Eastern Caribbean Supreme Court and has worked for a BVI and Cayman Islands offshore law firm.

McGee previously worked as general counsel in the Special Situations team, Energy and Technology Fund, at the globally focused hedge fund RAB Capital plc. McGee was also the CEO of an AIM quoted natural resources business before setting up an independent consultancy company to provide general counsel services to the alternative investment sector. That work extended to the European medical cannabis space from the early part of 2018 and included working with networks of entrepreneurs, professional service providers and investors in the industry around the world.

“The global cannabis industry is highly regulated with varying laws by Country. We recognized the need to bring on a Chief Legal Officer and Regulatory Affairs position early in our growth plan to ensure we are on top of the cannabis regulations as they change. This gives the Company the edge in the industry in order to quickly adapt to conform with regulation and monetize a return for our shareholders. McGee is one of the very few city professionals who have actual experience in the Cannabis industry. He brings to the Company a breadth of legal experience in private equity and investment banking which fits well with our fundraising strategy. In addition, we are moving at a rapid speed to grow Winchester not only organically but also by way of acquisition. McGee will be an integral part of our aggressive acquisition strategy.” Explains Faz Moshfeghi, CEO of Winchester.

For more information, please visit www.winchestermd.com
On Behalf of the Board,
Faz Moshfeghi

CEO
Info@winchestermd.com
About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

Winchester MD Signs JV to Cultivate Industrial Hemp in Ronda, Spain and Acquires 1.6 Million EU Registered Seeds

LONDON, UK, May 9, 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that on April 30, 2019, the Company signed a joint venture agreement (“JV”)  with a land owner in Ronda, Spain for the purpose of cultivating industrial hemp (“Cultivation Property”). In addition, the Company has purchased 1.6 million European Union registered hemp seeds for 2019 hemp cultivation on the Cultivation Property as well as for sale on the retail CBD superstore operated by Winchester MD (www.hempelf.com). The Company’s agreement with the land owner is to invest in all farming costs including but not limited to seeds, labour, irrigation, and cultivation in exchange for 80% of the economics from the JV.

Faz Moshfeghi, CEO of Winchester MD, commented, “The cultivation plot comprises of 20 hectares of irrigated farming land currently growing oats in the south of Spain. We have started to revamp the irrigation system to supply water across the land from the existing underground freshwater wells situated on the property. Our seeds will be germinated indoors using a nearby greenhouse to ensure a high germination rate. We expect to have the seedlings in the ground within the next 3 weeks and have engaged a local labour agency who will manage the hiring and payroll of our workforce for the project. This is the first biomass crop for Winchester and we are already having discussions with a European extraction partners in order to extract our biomass and produce CBD Isolate, which is expected by October 2019. Based on historic data for the performance of the EU-registered seeds and the experience of our farmers, we anticipate cultivating approximately 100,000 kilograms of hemp biomass in 2019 from the Cultivation Property. We are also expecting to extract 3,000 to 4,000 kilograms of CBD isolate, which at the current average price per kilogram, would yield gross sales in the range of €18 million to €24 million.”

For more information, please visit www.winchestermd.com

On Behalf of the Board,
Farzad Moshfeghi
CEO
Info@winchestermd.com
About Winchester MD Limited

Winchester MD is a vertically integrated, European cannabis company based in London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue-producing, online retail superstore platform Hemp Elf www.hempelf.com. The Company offers a variety of CBD branded products through its online superstore and continues to develop and market new products in the CBD Wellness category. In 2019, the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD Wellness, and research and development.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

Winchester Attends First Wednesdays – The European Cannabis Professional Network

LONDON, UK, May 2, 2019 –WINCHESTER MD LIMITED (“Winchester” or the “Company”) attended the First Wednesday Cannabis Professional Network event on May 1, 2019  in London, UK sponsored by Canaccord and DAC Beachcroft. First Wednesdays is powered by Hanway Associates, London’s global cannabis consultancy –your knowledge & network partner.London hosts include Canaccord Genuity Limited’s Head of European Cannabis Investment banking team, Tristan Gervais, as well as other.

“The evening is brimming with a slightly breathless, nothing-can-stop-us zeal – a brand of enthusiasm I recognise from the years I spent in California covering Silicon Valley for this magazine.”– Rhys Blakely, The Times

Faz, CEO of Winchester, commented “This is a great event for entrepreneurs and is held on the first Wednesday of every month. The cannabis industry in Europe has been evolving at a rapid speed and events like this bring like minded people together to discuss challenges and opportunities facing all of us in the global legalization of Cannabis. Our team at Winchester strives to continuously adapt our business model with the changes in legalization while maintaining quality products for our customers who order through our on-line CBD Wellness retail platform www.hempelf.com.”

In attendance at the event were Faz Moshfeghi, CEO Winchester Corporate, Marti Moshfeghi, CEO Winchester CBD Wellness, Dan Kriznic VP Public Markets and Business Development and Mike Kriznic, Italy Country manager.

For more information, please visit www.winchestermd.com

On Behalf of the Board,
Faz Moshfeghi
CEO
Info@winchester-md.com

About Winchester MD Limited

Winchester is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail platform Hemp Elf www.hempelf.com. The Company offers a variety of CBD products through its on line store and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector including with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness, R&D and clinics/education.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.